Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
114.2 SEK | +0.13% | -1.63% | +13.24% |
Apr. 03 | Nordic Shares Rose Wednesday; BW LPG Led Increases | DJ |
Mar. 28 | Nordic Shares Decreased Thursday; BioGaia Series B Posted Biggest Loss | DJ |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- This company will be of major interest to investors in search of a high dividend stock.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 28.6 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.24% | 1.07B | B- | ||
-3.89% | 88.14B | A- | ||
+1.45% | 40.51B | A- | ||
-15.94% | 31.67B | B- | ||
+53.49% | 24.62B | A | ||
-14.50% | 15.65B | C | ||
-14.38% | 12.07B | B- | ||
-9.12% | 11.97B | D+ | ||
-42.56% | 11.61B | B | ||
+6.37% | 8.81B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIOG B Stock
- Ratings BioGaia AB